Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer

被引：0
|
作者：
O'Rourke, Kate
机构：
来源：
CANCER | 2022年 / 128卷 / 05期
关键词：
D O I：
10.1002/cncr.34102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：938 / 938
页数：1
相关论文
共 50 条
  • [21] Non-small cell Lung Cancer: Trastuzumab and Deruxtecan Compination has an anti-cancer effect
    Metzger, Leandra
    PNEUMOLOGIE, 2021, 75 (11): : 835 - 835
  • [22] Patritumab Deruxtecan Is Efficacious in EGFR-Mutant Non-Small Cell Lung Cancer
    Zhang, H.
    Yu, X.
    Ye, J.
    Li, H.
    Hu, J.
    Tan, Y.
    CANCER DISCOVERY, 2023, 13 (12) : 2501 - 2501
  • [23] The role of HER2/neu expression and trastuzumab in non-small cell lung cancer
    Hirsch, FR
    Langer, CJ
    SEMINARS IN ONCOLOGY, 2004, 31 (01) : 75 - 82
  • [24] Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
    Azar, Ibrahim
    Alkassis, Samer
    Fukui, Jami
    Alsawah, Fares
    Fedak, Kalub
    Al Hallak, Mohammed Najeeb
    Sukari, Ammar
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 103 - 114
  • [25] Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study
    Yang, G.
    Xu, H.
    Xu, F.
    Yang, L.
    Li, H.
    Zhang, S.
    Yang, Y.
    Ai, X.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S672 - S673
  • [26] A Case of Metastatic HER2-Amplified Non-Small-Cell Lung Cancer (NSCLC) Treated with Trastuzumab Deruxtecan
    Yun, K.
    Bazhenova, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E38 - E38
  • [27] Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial (vol 41, pg 4852, 2023)
    Goto, Koichi
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    de Langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Kuo, Chih-Hsi
    Yang, James Chih-Hsin
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Feng, Wenqin
    Tsuchihashi, Zenta
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (04) : 485 - 485
  • [28] The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
    Nagasaka, Misako
    Singh, Vijendra
    Baca, Yasmine
    Sukari, Ammar
    Kim, Chul
    Mamdani, Hirva
    Spira, Alexander, I
    Uprety, Dipesh
    Bepler, Gerold
    Kim, Edward S.
    Raez, Luis E.
    Pai, Sachin Gopalkrishna
    Ikpeazu, Chukwuemeka
    Oberley, Matthew
    Feldman, Rebecca
    Xiu, Joanne
    Korn, W. Michael
    Wozniak, Antoinette J.
    Borghaei, Hossein
    Liu, Stephen, V
    CLINICAL LUNG CANCER, 2022, 23 (01) : 52 - 59
  • [29] Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
    Ahn, Beung-Chul
    Han, Ye-Jeong
    Kim, Hye Ryun
    Hong, Min Hee
    Cho, Byoung Chul
    Lim, Sun Min
    CANCER RESEARCH AND TREATMENT, 2023, 55 (02): : 488 - 497
  • [30] Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report
    He, Xincheng
    Hou, Lei
    Bai, Jun
    Sun, Chao
    Wang, Dongjie
    An, Gaili
    ANTI-CANCER DRUGS, 2024, 35 (01) : 101 - 108
12345